Mirabegron as effective as oxybutynin for ureteral stent symptoms
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista da Associação Médica Brasileira (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001301793 |
Resumo: | SUMMARY OBJECTIVE: Ureteral stents usually cause pain and lower urinary tract discomfort. This study aimed to compare the effect of mirabegron with oxybutynin in relieving ureteral stent-related symptoms over time. METHODS: A prospective, longitudinal, randomized, single-blinded study was conducted. Patients who had a ureteral stent inserted after urolithiasis treatment were classified into two groups and received either oxybutynin 5 mg/day (Group O) or mirabegron 50 mg/day (Group M). The Ureteral Stent Symptoms Questionnaire (USSQ) was applied on the 3rd, 6th, and 15th postoperative days. Group domain scores were compared, and a mixed linear model was used to better assess score differences. RESULTS: Ureteral Stent Symptoms Questionnaire scores were similar in both groups during all three postoperative days (p>0.05). A longitudinal analysis showed that global quality of life and general health improved over time, independently of the use of any of the medications (p<0.05), while urinary symptoms and body pain scores were lower over time in participants receiving oxybutynin. CONCLUSION: Both mirabegron and oxybutynin are equivalent in relieving ureteral stent symptoms. Moreover, some stent symptoms seem to decrease over time despite the use of medication. |
id |
AMB-1_be19a27c7601c85115c61aafc1b8e56f |
---|---|
oai_identifier_str |
oai:scielo:S0104-42302021001301793 |
network_acronym_str |
AMB-1 |
network_name_str |
Revista da Associação Médica Brasileira (Online) |
repository_id_str |
|
spelling |
Mirabegron as effective as oxybutynin for ureteral stent symptomsUreterStentsUreteroscopyKidney calculiSUMMARY OBJECTIVE: Ureteral stents usually cause pain and lower urinary tract discomfort. This study aimed to compare the effect of mirabegron with oxybutynin in relieving ureteral stent-related symptoms over time. METHODS: A prospective, longitudinal, randomized, single-blinded study was conducted. Patients who had a ureteral stent inserted after urolithiasis treatment were classified into two groups and received either oxybutynin 5 mg/day (Group O) or mirabegron 50 mg/day (Group M). The Ureteral Stent Symptoms Questionnaire (USSQ) was applied on the 3rd, 6th, and 15th postoperative days. Group domain scores were compared, and a mixed linear model was used to better assess score differences. RESULTS: Ureteral Stent Symptoms Questionnaire scores were similar in both groups during all three postoperative days (p>0.05). A longitudinal analysis showed that global quality of life and general health improved over time, independently of the use of any of the medications (p<0.05), while urinary symptoms and body pain scores were lower over time in participants receiving oxybutynin. CONCLUSION: Both mirabegron and oxybutynin are equivalent in relieving ureteral stent symptoms. Moreover, some stent symptoms seem to decrease over time despite the use of medication.Associação Médica Brasileira2021-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001301793Revista da Associação Médica Brasileira v.67 n.12 2021reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.20210711info:eu-repo/semantics/openAccessJaworski,PauloMello,Gregório FadelFerreira,Guilherme MonteiroOliveira,Maria HelenaFraga,Rogerio deeng2021-12-09T00:00:00Zoai:scielo:S0104-42302021001301793Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2021-12-09T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false |
dc.title.none.fl_str_mv |
Mirabegron as effective as oxybutynin for ureteral stent symptoms |
title |
Mirabegron as effective as oxybutynin for ureteral stent symptoms |
spellingShingle |
Mirabegron as effective as oxybutynin for ureteral stent symptoms Jaworski,Paulo Ureter Stents Ureteroscopy Kidney calculi |
title_short |
Mirabegron as effective as oxybutynin for ureteral stent symptoms |
title_full |
Mirabegron as effective as oxybutynin for ureteral stent symptoms |
title_fullStr |
Mirabegron as effective as oxybutynin for ureteral stent symptoms |
title_full_unstemmed |
Mirabegron as effective as oxybutynin for ureteral stent symptoms |
title_sort |
Mirabegron as effective as oxybutynin for ureteral stent symptoms |
author |
Jaworski,Paulo |
author_facet |
Jaworski,Paulo Mello,Gregório Fadel Ferreira,Guilherme Monteiro Oliveira,Maria Helena Fraga,Rogerio de |
author_role |
author |
author2 |
Mello,Gregório Fadel Ferreira,Guilherme Monteiro Oliveira,Maria Helena Fraga,Rogerio de |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Jaworski,Paulo Mello,Gregório Fadel Ferreira,Guilherme Monteiro Oliveira,Maria Helena Fraga,Rogerio de |
dc.subject.por.fl_str_mv |
Ureter Stents Ureteroscopy Kidney calculi |
topic |
Ureter Stents Ureteroscopy Kidney calculi |
description |
SUMMARY OBJECTIVE: Ureteral stents usually cause pain and lower urinary tract discomfort. This study aimed to compare the effect of mirabegron with oxybutynin in relieving ureteral stent-related symptoms over time. METHODS: A prospective, longitudinal, randomized, single-blinded study was conducted. Patients who had a ureteral stent inserted after urolithiasis treatment were classified into two groups and received either oxybutynin 5 mg/day (Group O) or mirabegron 50 mg/day (Group M). The Ureteral Stent Symptoms Questionnaire (USSQ) was applied on the 3rd, 6th, and 15th postoperative days. Group domain scores were compared, and a mixed linear model was used to better assess score differences. RESULTS: Ureteral Stent Symptoms Questionnaire scores were similar in both groups during all three postoperative days (p>0.05). A longitudinal analysis showed that global quality of life and general health improved over time, independently of the use of any of the medications (p<0.05), while urinary symptoms and body pain scores were lower over time in participants receiving oxybutynin. CONCLUSION: Both mirabegron and oxybutynin are equivalent in relieving ureteral stent symptoms. Moreover, some stent symptoms seem to decrease over time despite the use of medication. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001301793 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001301793 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/1806-9282.20210711 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Médica Brasileira |
publisher.none.fl_str_mv |
Associação Médica Brasileira |
dc.source.none.fl_str_mv |
Revista da Associação Médica Brasileira v.67 n.12 2021 reponame:Revista da Associação Médica Brasileira (Online) instname:Associação Médica Brasileira (AMB) instacron:AMB |
instname_str |
Associação Médica Brasileira (AMB) |
instacron_str |
AMB |
institution |
AMB |
reponame_str |
Revista da Associação Médica Brasileira (Online) |
collection |
Revista da Associação Médica Brasileira (Online) |
repository.name.fl_str_mv |
Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB) |
repository.mail.fl_str_mv |
||ramb@amb.org.br |
_version_ |
1754212836961157120 |